Jean-François Stephan
Biographic Data
| ID | 1847925 |
|---|---|
| NAME | Jean-François Stephan |
| GIVEN NAMES | Jean-François |
| FAMILY NAME | Stephan |
| SIGNATURE | STEPHAN J |
| AFFILIATIONS | Physician and Psychotherapist in Private Practice, Montréal, QC, Canada |
| ORCID | 0009-0000-7376-208X |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Experiential dimension of psilocybin-assisted therapy training
The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocybin-assisted therapy training is crucial, as it can affect treatment safety, effectiveness and accessibility. As such, the ethical and practical issues associated with such a training standard require timely consideration in jurisdictions where this intervention is endorsed and integrated into healthcare. We be…
Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interactions between psilocybin and other psychotropic drugs, clinical trials require that patients discontinue their antidepressants before study entry to isolate the benefits of psilocybin and to minimize the risk of adverse events. We present the first case of an adult patient with DTD who received psilocybin-…
No prominent works on this page.
Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy
Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interactions between psilocybin and other psychotropic drugs, clinical trials require that patients discontinue their antidepressants before study entry to isolate the benefits of psilocybin and to minimize the risk of adverse events. We present the first case of an adult patient with DTD who received psilocybin-…
Experiential dimension of psilocybin-assisted therapy training
The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocybin-assisted therapy training is crucial, as it can affect treatment safety, effectiveness and accessibility. As such, the ethical and practical issues associated with such a training standard require timely consideration in jurisdictions where this intervention is endorsed and integrated into healthcare. We be…
Hallucinogen (2 works) · Psilocybin (2 works) · Psychedelics and Drug Studies (2 works) · Psychiatry (2 works) · Psychology (2 works) · Adverse effect (1 work) · Alternative medicine (1 work) · Antidepressant (1 work) · Anxiety (1 work) · Chemical synthesis and alkaloids (1 work)